[HTML][HTML] Magnesium sulphate at 30 to 34 weeks' gestational age: neuroprotection trial (MAGENTA)-study protocol
CA Crowther, PF Middleton, D Wilkinson… - BMC pregnancy and …, 2013 - Springer
Background Magnesium sulphate is currently recommended for neuroprotection of preterm
infants for women at risk of preterm birth at less than 30 weeks' gestation, based on high …
infants for women at risk of preterm birth at less than 30 weeks' gestation, based on high …
[PDF][PDF] Magnesium sulphate at 30 to 34 weeks' gestational age: neuroprotection trial (MAGENTA)-study protocol
CA Crowther, PF Middleton, D Wilkinson, P Ashwood… - 2013 - researchgate.net
Background: Magnesium sulphate is currently recommended for neuroprotection of preterm
infants for women at risk of preterm birth at less than 30 weeks' gestation, based on high …
infants for women at risk of preterm birth at less than 30 weeks' gestation, based on high …
Magnesium sulphate at 30 to 34 weeks' gestational age: neuroprotection trial (MAGENTA)--study protocol.
CA Crowther, PF Middleton, D Wilkinson… - BMC Pregnancy and …, 2013 - europepmc.org
Background Magnesium sulphate is currently recommended for neuroprotection of preterm
infants for women at risk of preterm birth at less than 30 weeks' gestation, based on high …
infants for women at risk of preterm birth at less than 30 weeks' gestation, based on high …
Magnesium sulphate at 30 to 34 weeks' gestational age: Neuroprotection trial (MAGENTA)-study protocol
CA Crowther, PF Middleton… - BMC Pregnancy …, 2013 - research.sahmri.org.au
Background: Magnesium sulphate is currently recommended for neuroprotection of preterm
infants for women at risk of preterm birth at less than 30 weeks' gestation, based on high …
infants for women at risk of preterm birth at less than 30 weeks' gestation, based on high …
[PDF][PDF] Magnesium sulphate at 30 to 34 weeks' gestational age: neuroprotection trial (MAGENTA)-study protocol
CA Crowther, PF Middleton, D Wilkinson, P Ashwood… - 2013 - scienceopen.com
Background: Magnesium sulphate is currently recommended for neuroprotection of preterm
infants for women at risk of preterm birth at less than 30 weeks' gestation, based on high …
infants for women at risk of preterm birth at less than 30 weeks' gestation, based on high …
Magnesium sulphate at 30 to 34 weeks' gestational age: neuroprotection trial (MAGENTA)--study protocol
CA Crowther, PF Middleton, D Wilkinson, P Ashwood… - 2013 - pubmed.ncbi.nlm.nih.gov
Background Magnesium sulphate is currently recommended for neuroprotection of preterm
infants for women at risk of preterm birth at less than 30 weeks' gestation, based on high …
infants for women at risk of preterm birth at less than 30 weeks' gestation, based on high …
[PDF][PDF] Magnesium sulphate at 30 to 34 weeks' gestational age: neuroprotection trial (MAGENTA)-study protocol
CA Crowther, PF Middleton, D Wilkinson, P Ashwood… - 2013 - cyberleninka.org
Background: Magnesium sulphate is currently recommended for neuroprotection of preterm
infants for women at risk of preterm birth at less than 30 weeks' gestation, based on high …
infants for women at risk of preterm birth at less than 30 weeks' gestation, based on high …
[HTML][HTML] Magnesium sulphate at 30 to 34 weeks' gestational age: neuroprotection trial (MAGENTA)-study protocol
CA Crowther, PF Middleton… - BMC …, 2013 - bmcpregnancychildbirth …
Magnesium sulphate is currently recommended for neuroprotection of preterm infants for
women at risk of preterm birth at less than 30 weeks' gestation, based on high quality …
women at risk of preterm birth at less than 30 weeks' gestation, based on high quality …
[PDF][PDF] Magnesium sulphate at 30 to 34 weeks' gestational age: neuroprotection trial (MAGENTA)-study protocol
CA Crowther, PF Middleton, D Wilkinson, P Ashwood… - 2013 - academia.edu
Background: Magnesium sulphate is currently recommended for neuroprotection of preterm
infants for women at risk of preterm birth at less than 30 weeks' gestation, based on high …
infants for women at risk of preterm birth at less than 30 weeks' gestation, based on high …
[HTML][HTML] Magnesium sulphate at 30 to 34 weeks' gestational age: neuroprotection trial (MAGENTA)-study protocol
CA Crowther, PF Middleton, D Wilkinson… - BMC Pregnancy and …, 2013 - ncbi.nlm.nih.gov
Background Magnesium sulphate is currently recommended for neuroprotection of preterm
infants for women at risk of preterm birth at less than 30 weeks' gestation, based on high …
infants for women at risk of preterm birth at less than 30 weeks' gestation, based on high …